Another retrospective study (40) compared the efficacy of lenvatinib + toripalimab (PD-1 monoclonal antibody) + HAIC (LeToHAIC, n = 71) with that of lenvatinib (n = 86) in patients with advanced HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.